Human Ebola virus infection results in substantial immune activation. - Wikidata - awgldk - TriplyDB

Human Ebola virus infection results in substantial immune activation.

Human Ebola virus infection results in substantial immune activation.

http://www.wikidata.org/entity/Q35485277

about

Presence and Persistence of Ebola or Marburg Virus in Patients and Survivors: A Rapid Systematic Review Convalescent plasma: new evidence for an old therapeutic tool?Clinical development of Ebola vaccines The Role of Cytokines and Chemokines in Filovirus Infection Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Evaluating the frequency of asymptomatic Ebola virus infection Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection.Retinal Pigment Epithelial Cells are a Potential Reservoir for Ebola Virus in the Human Eye.Molecular mechanisms of Ebola virus pathogenesis: focus on cell death.Ebola vaccine R&D: Filling the knowledge gaps.Unique human immune signature of Ebola virus disease in Guinea.Robust and sustained immune activation in human Ebola virus infection.Ebola Virus Disease: Experience and Decision Making for the First Patients outside of Africa.Immunological features underlying viral hemorrhagic fevers Reduced Plasmodium Parasite Burden Associates with CD38+ CD4+ T Cells Displaying Cytolytic Potential and Impaired IFN-γ Production The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses.Blood kinetics of Ebola virus in survivors and nonsurvivors.Relationship Between Ebola Virus Real-Time Quantitative Polymerase Chain Reaction-Based Threshold Cycle Value and Virus Isolation From Human Plasma.Uveitis and Systemic Inflammatory Markers in Convalescent Phase of Ebola Virus Disease.Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease.Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection.Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses.Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination.Impaired T Cell-dependent Humoral Immune Response Associated with Juvenile-onset Recurrent Respiratory Papillomatosis Progression Characterization of Human CD8 T Cell Responses in Dengue Virus-Infected Patients from India Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus.Human Zika infection induces a reduction of IFN-γ producing CD4 T-cells and a parallel expansion of effector Vδ2 T-cells.Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus Clinical Evaluation of Ebola Virus Disease Therapeutics.Ebola Virus Disease in Humans: Pathophysiology and Immunity.Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses.Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study.Strategies to induce broadly protective antibody responses to viral glycoproteins.Molecular pathogenesis of viral hemorrhagic fever.Host Factors Involved in Ebola Virus Replication.

P2860

Q26765404-C671CD21-081F-4E1C-9CCA-6FCA516C327A Q26775412-6BBF416A-72C6-4306-8FE6-E09274DCD656 Q26775792-23926219-2772-44D4-9FA1-168ED9F723BA Q26778003-F142B96A-0872-4F8D-A55B-5F7E420C0895 Q26801423-9FDEC25F-4749-463F-AE43-5E1DDFE1167A Q28397866-62447E16-5819-466E-A731-B7DC9927F354 Q29994671-E1478A70-67DC-4731-B3BF-64CCB211A1BA Q30251098-D2307BCD-FA38-4DB5-96AF-F9AF8879CE30 Q33715773-BB58638C-F741-48AF-A634-D542E4C47B23 Q33758034-C8F64F22-9848-4C23-A112-7F5D2C532E43 Q33909208-ED3AFC7C-CC6C-4BE6-A372-D083F71F5E9B Q34478514-C59D4B0A-8711-46EF-A92B-74275F129085 Q34504883-BFB99A06-B23C-492A-9239-C5D365FD4B4A Q34525050-EDEE1839-1774-4494-9C5D-BE9B9D4AFE1F Q35485733-9421686B-56ED-4956-805C-8368B950EA96 Q35719946-BDB44D68-DC59-43D7-B16B-389A4360C81E Q36122433-5C5381E4-E6EE-4A51-B0DB-4BD848406334 Q36143186-D579BAC8-9A06-44E9-8B18-BB6579E5FC05 Q36216308-993207DE-D3BD-4B9E-9866-757E612E3A4F Q36335941-695403FF-3775-410E-BB0E-DF20DC629738 Q36363682-96C4BC1D-7D0D-4349-8FE0-C69A3BFFB6F1 Q36525242-45B32263-B8FD-4E8A-9D71-F4FAA8B22A5C Q36562881-CBE9806D-28BE-435C-A00C-24D284D2D449 Q36775011-03C7751F-A0E6-455E-8FCD-942557DAB6F6 Q36947021-19535AB9-417E-44BC-A6D8-6056B1688407 Q37163676-3991818F-5ACA-4CA5-BC76-035CB1C231EA Q37320688-0A308BF6-1E4A-4985-B5C0-8E89FECD278C Q37399606-9D8538C0-C6CA-4D37-A9B2-55CEC2279D18 Q37448371-FA32FF16-0A34-4365-AF1C-F8F0FCA3B305 Q37593571-ED9C17C9-7C05-4526-B87A-D481BAE57F78 Q38157432-37EB4E75-D497-47E3-90E3-C991B9BD2B75 Q38599899-DFFF4832-1C8D-461A-A19F-11FE03F78F69 Q38617605-41525323-A118-4264-BF4A-828B90304FF7 Q38707770-08169284-5704-4277-90EF-565D386682A7 Q38848145-5253E8F2-5B85-42A1-8220-BAFE439938AE Q38848150-E5B448DE-63BA-48D0-83CE-AE8F7F9C73C7 Q38856313-DCF197BD-0C65-4B47-9B95-58438D80F173 Q39170802-9293C5F3-208E-4C82-A73C-EFDFD06FB81D Q39337289-58FF6B35-8539-4611-B2B9-4258AB861215 Q39436358-CD2B9BED-DB25-4E78-B2EB-A0A723450115

P2860

Human Ebola virus infection results in substantial immune activation.

http://www.wikidata.org/entity/Q35485277

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Human Ebola virus infection results in substantial immune activation.

@ast

Human Ebola virus infection results in substantial immune activation.

@en

type

label

Human Ebola virus infection results in substantial immune activation.

@ast

Human Ebola virus infection results in substantial immune activation.

@en

prefLabel

Human Ebola virus infection results in substantial immune activation.

@ast

Human Ebola virus infection results in substantial immune activation.

@en

P1433

Q35485277-CDFC6FFB-A4CA-4D75-8909-B1E2094DD6EC

P1476

Q35485277-EE072419-DC66-4B3B-BF3E-B2D958D28E72

P2093

Q35485277-0CD4832E-D5BD-418C-99C3-B07B174882D7

Q35485277-1CD45313-CD85-4090-8918-7C95D3944937

Q35485277-2085C179-2CD0-4491-9560-DB9EC64C5AF1

Q35485277-5278AC3E-B691-4875-9F1D-FCEAF14857B5

Q35485277-5421BBD6-788D-4285-942D-042CA13FB123

Q35485277-83DD11B2-559B-439C-8CBD-86B164B08E18

Q35485277-930A0E54-705A-47AC-B84F-58286504FFA7

Q35485277-B42D8F9A-48BE-4F98-BB7F-F4E0D2EA09BB

Q35485277-CEDE32B2-9356-43CA-B543-AEEDDB184FB2

Q35485277-F085B7C6-5A2A-4F52-AE3D-46C9594A1F46

P2860

Q35485277-0448D328-E485-4FE5-B54A-A88F6BD187AD

Q35485277-09079250-1BAF-4F97-B029-C5D530622BC8

Q35485277-0ECC587E-845B-43B9-BE8B-946DFB29003B

Q35485277-0FB2D960-FF57-4DBC-B862-9C74E659A356

Q35485277-1BEADF2D-B083-4085-BE8B-3DDC98075ADA

Q35485277-1E1CE905-73DB-48CB-94FC-9B5492DF2941

Q35485277-2EDD8060-FDB5-49EE-B989-2B91E0D2B005

Q35485277-3FB7E436-C4E8-41BB-B42D-9499121D2A05

Q35485277-41F5940D-8F34-4170-A430-4D3A1B05FEDC

Q35485277-51C4359B-A92F-4376-B080-76A0D08B30DF

P304

Q35485277-AC458E88-709B-44C7-9245-FB61B75E9E56

P31

Q35485277-F3EB991C-0052-4CBB-A453-139A09C7853A

P356

Q35485277-455899F5-F4AE-4B86-A584-B56979B99452

P407

Q35485277-D3654954-B9EF-404E-AB36-E1FE41D086C6

P433

Q35485277-3FF92C69-FEE5-49D4-B6E8-323C6D2304A3

P478

Q35485277-4CE3AEBC-8B68-4B64-A5AC-6633EAC7C34F

P50

Q35485277-5BF64CCC-9D2E-4433-A6E8-F75FB2094253

Q35485277-5DDB675F-8A02-4FA1-A7C8-DFCCE9784C9A

Q35485277-62B49522-3559-4113-9844-94399F959CC4

Q35485277-9F86FDF1-227E-4C04-94CE-A8022D7F7B44

Q35485277-A660A8BA-3337-4A10-815B-8A3EA3DE9608

Q35485277-D4BCBD73-1690-47D1-B4BC-C9C7B6C83F8B

Q35485277-E01DA2AD-6F61-4B95-99CA-F2064095A0EE

P577

Q35485277-0CFE2E5A-4603-4890-B729-144813EC5B76

P698

Q35485277-4B8015C7-3E75-41C2-AF69-A47E65C8C263

P921

Q35485277-939799B0-422E-429E-BE7D-1E05CE918259

P932

Q35485277-9B05254A-4B2F-4565-95F1-57267ECF46FF

P356

PNAS.1502619112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Human Ebola virus infection results in substantial immune activation.

@en

P2093

Ali H Ellebedy

http://www.w3.org/2001/XMLSchema#string

Bruce S Ribner

http://www.w3.org/2001/XMLSchema#string

Carl W Davis

http://www.w3.org/2001/XMLSchema#string

Christina F Spiropoulou

http://www.w3.org/2001/XMLSchema#string

G Marshall Lyon

http://www.w3.org/2001/XMLSchema#string

Inger Damon

http://www.w3.org/2001/XMLSchema#string

Jay Varkey

http://www.w3.org/2001/XMLSchema#string

John Sidney

http://www.w3.org/2001/XMLSchema#string

Rafi Ahmed

http://www.w3.org/2001/XMLSchema#string

Shelley Campbell

http://www.w3.org/2001/XMLSchema#string

P2860

Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis

Ebola virus vaccines: an overview of current approaches

Restoring function in exhausted CD8 T cells during chronic viral infection

Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels.

Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Clinical features and pathobiology of Ebolavirus infection.

The Ebola virus VP35 protein functions as a type I IFN antagonist.

P304

4719-4724

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1502619112

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Alessandro Sette

Stuart T Nichol

Colleen S. Kraft

P577

2015-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25775592

http://www.w3.org/2001/XMLSchema#string

P921

P932

4403189

http://www.w3.org/2001/XMLSchema#string